Higher efavirertz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations

AIDS

Volumn 18, Issue 15, 2004, Pages 2091-2094

  González De Requena, Daniel ^a   Gallego, Oscar ^a   Corral, Angélica ^a   Jiménez Nácher, Inmaculada ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OXAZINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; GENE SEQUENCE; HUMAN; PRIORITY JOURNAL; VIROLOGY; VIRUS LOAD; VIRUS MUTATION; BLOOD; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; TREATMENT FAILURE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL LOAD;

EID: 7744239168     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200410210-00017     Document Type: Article

References (8)

1. Lange JM. Efficacy and durability of nevirapine in antiretroviral drug naive patients. J Acquired Immune Defic Syndr 2003; 34 (Suppl. 1):53-58.
2. Joly V, Yeni P. Non nucleoside reverse transcriptase inhibitors. AIDS Rev 1999; 1:37-44.
3. Staszewski S, Morales-Ramirez J, Tashima K, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 25:1865-1873.
4. Hanna G, D'Aquila R. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis 2001; 32:774-782.
5. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001; 75:4999-5008.
6. Antinori A, Zaccarelli M, Cingolani A, Forbici F, Rizzo M, Trotta M, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002; 18:835-858.
7. Marzolini C, Telenti A, Decosterd L, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75.
8. Titier K, Lagrange F, Pehourcq F, Edno-Mcheik L, Moore N, Molimard M. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma. Therapeut Drug Monit 2002; 24:417-424.